Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )

Trial Profile

Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Z 360 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms ZIPANG
  • Sponsors Zeria
  • Most Recent Events

    • 01 Aug 2017 Primary endpoint (Overall Survival) has not been met as per the results published in the Cancer Chemotherapy and Pharmacology
    • 01 Aug 2017 Results (data cut-off date November 30, 2015) published in the Cancer Chemotherapy and Pharmacology
    • 29 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top